A leukemia survivor recalls how bonding with other patients helped his hospital stays go by faster and became a key part of his emotional healing.
News|Videos|October 9, 2026
Rina-S Shows 45.9% Response Rate in Platinum-Resistant Ovarian Cancer
Author(s)Dr. Elizabeth K. Lee , Kaitlyn M. Le
Rinatabart sesutecan shrank tumors in 45.9% of patients with platinum-resistant ovarian cancer in a phase 2 study, with responses lasting a median of 12.1 months.
Advertisement
Advertisement
The investigational drug rinatabart sesutecan (Rina-S) shrank tumors in 45.9% of patients with platinum-resistant ovarian cancer, a form of ovarian cancer that returns or grows soon after platinum-based chemotherapy, according to results from Part C of the phase 1/2 RAINFOL-01 trial. Responses lasted a median of 12.1 months, and the drug showed activity in patients regardless of how much of its target protein their tumors carried.
Related to this article
Tecentriq plus chemotherapy lowered the risk of cancer returning or death by 50% versus chemotherapy alone in patients with stage 3 dMMR colon cancer.
Median progression-free survival reached 24.9 months with Tukysa plus Herceptin and Perjeta versus 16.3 months with placebo plus Herceptin and Perjeta.
Breast cancer survivor Sue Weldon discusses survivorship gaps, integrative therapies alongside treatment and why caregivers should prioritize themselves.
A long-term metastatic ovarian cancer survivor explains how a trifecta of hope, purpose and grace has shaped her life through years of treatment.
Learn how nipple-sparing mastectomy, including endoscopic approaches, may help preserve appearance, reduce scarring and support breast cancer recovery.
After 17 and a half years with metastatic primary peritoneal cancer, a former hospital executive explains how an AI health agent helped her after discharge.
The FDA approval is based on the phase 3 BRUIN CLL-313 trial, in which 94% of patients responded to Jaypirca compared with 81% who received chemoimmunotherapy.
Advertisement
Advertisement